Multiple myeloma, a haematological malignancy of the plasma cell, is still largely incurable. The introduction of proteasome inhibitors such as bortezomib has significantly improved patient survival, however bortezomib resistance is still a major hurdle which requires new therapeutic options. One such option may be inhibitors to sphingolipid metabolism.
|Number of pages||1|
|Publication status||Published - 2019|
|Event||48th ISEH Annual Scientific Meeting - Brisbane Convention & Exhibition Centre, Brisbane, Australia|
Duration: 22 Aug 2019 → 25 Aug 2019
- multiple myeloma
- Sphingosine kinase 2
- Bortezomib resistance